Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAfter a first Mounjaro pen, most people expect dramatic appetite suppression and rapid weight loss within days. The reality is quieter than that. The 2.5 mg starting dose is designed to help your body adjust to tirzepatide, not to deliver its full effect — so what you notice in week one is usually less about weight and more about how your body is settling in. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people reach out to us after their first pen asking whether something has gone wrong. They have injected on schedule, done everything right, and yet the scales have barely moved. This is not a sign of failure, it is exactly how tirzepatide is designed to behave at 2.5 mg.
The starting dose exists to let your system acclimatise to a new class of medicine. Tirzepatide activates both the GIP and GLP-1 receptors involved in appetite and blood-sugar regulation, and that process takes weeks to reach meaningful therapeutic levels at the doses where clinical results were recorded. The large-scale SURMOUNT-1 trial, published in the New England Journal of Medicine, followed participants over 72 weeks, not four days. Expecting a single pen to replicate those outcomes is like judging a marathon by the first hundred metres.
The full Mounjaro treatment overview explains how the titration schedule builds toward the doses where the trial evidence sits. In short: week one is an introduction, not a verdict.
That said, plenty of people do notice something after their first injection, it just tends to be physical adjustment rather than weight change. The most commonly reported experiences in the first week include mild nausea (especially in the hours after injection), looser stools, a tendency to feel full more quickly than usual, and occasional fatigue or a dull headache. The NHS tirzepatide page lists these as known common effects that typically settle within days to a couple of weeks.
Injection-site redness or a small lump is also normal and usually resolves quickly. Rotating between your abdomen, thigh and upper arm from pen to pen helps reduce this. If side effects feel severe or do not ease (particularly any significant stomach pain that spreads to your back) contact a healthcare professional promptly rather than waiting for your next check-in.
A note on the pen itself: it arrives by tracked DPD delivery in plain, unbranded packaging. Inside, you will find the KwikPen prefilled with four weekly doses at your starting strength, along with an information leaflet. Read the leaflet before you inject, the injection technique and storage guidance it contains cannot be summarised safely here, and the prescriber's notes from your nume consultation will complement it.
Some people report a noticeable reduction in appetite after a single pen. Others feel almost nothing. Both responses are within normal range at 2.5 mg, and neither predicts how the medicine will work for you at a higher, therapeutic dose.
Several factors shape first-pen experience: individual gastric-emptying rate, how recently you ate before injecting, your baseline gut sensitivity, and plain biological variation. There is no evidence that feeling less at 2.5 mg means the medicine will not work, and if you want to understand in detail what to expect from your Mounjaro pen after the first dose, that page walks through the full picture. If you are curious about what tends to change as doses increase, the dose-by-dose experience guide covers each step in detail.
One thing worth knowing on cost: the 2.5 mg pen costs the same as higher doses per pen from most providers. There is a broader context around pricing worth reading if you are comparing services, the Eli Lilly UK price increase page explains what changed in September 2025 and what that means for private treatment costs.
Most first-pen experiences do not need urgent review, but a few situations should prompt you to get in touch with your clinical team rather than waiting. Contact your prescriber if you experience persistent vomiting that stops you keeping fluids down, severe or radiating abdominal pain, signs of an allergic reaction, or any symptoms that feel disproportionate to what you were told to expect.
Equally, if you are unsure whether your response after one pen is typical (or you are questioning whether to continue) that conversation belongs with a clinician, not a forum. The guide on staying at 5 mg is useful context for people who reach the next dose and want to understand what holding there might mean. And if you want a broader view of how your response might develop over subsequent pens, the two-dose experience page picks up from where this one leaves off.
Our prescribers are available seven days a week for aftercare questions. If something does not feel right, reach out, that support is included as standard, not an extra.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.